The hardware giant is dealing with all this drama because it didn't prioritize Siri long ago.

ELNET has announced significant changes in its executive roster ahead of the 40th Annual Shareholders Meeting on June 25, 2026.

The company has unveiled new appointments and retirements of board members ahead of the extraordinary shareholders' meeting on September 16, 2026.

Challenger Gold, currently suspended from trading, is undergoing significant corporate changes behind the scenes. Its brokers are preparing a major capital raising of $80 million, aimed at strengthening the company’s financial position. Alongside this, there is a substantial reshuffle of both the board and management. Seasoned gold industry executive Peter Marrone is set to become the new chairman and will contribute a significant portion of the proposed funds. The company, which currently has a market capitalisation of $292 million, is positioning itself for a potential turnaround under Marrone's leadership. These moves signal a renewed focus on stabilising the business and enhancing investor confidence, with the capital raising and executive changes intended to lay the foundation for future growth and operational improvements in the gold sector.

Macworld Much talk in Silicon Valley lately has focused on the timing of Apple boss Tim Cook’s retirement. At the age of 65, and having publicly discussed his departure as far back as 2021, he isn’t...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) - Novo Nordisk (NYSE:NVO)’s head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday. Novo’s rare disease unit head, Ludovic Helfgott, who was already on the executive management team, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, the company said. Sylvest was one of two women on Novo’s 10-person executive management team. Well known to investors and analysts, she was a consistent presence alongside Chief Executive Officer Lars Fruergaard Jorgensen, Chief Financial Officer Karsten Munk Knudsen, and others on earnings calls. Novo’s statement on Thursday said that Sylvest had decided to leave and did not cite a reason. While some European pharmaceutical companies - including Swiss drugmakers Roche and Novartis (SIX:NOVN) - have abandoned global diverse workforce targets in response to recent U.S. executive orders, Novo Nordisk says it remains committed to its DEI programmes.